Elekta AB (publ)
Elekta AB (publ) (EKTAY) Stock Competitors & Peer Comparison
See (EKTAY) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EKTAY | $5.85 | -3.94% | 2.2B | -588.00 | -$0.01 | +2.22% |
| SRTOY | $18.34 | -0.86% | 181B | 60.00 | $0.31 | +0.42% |
| ESLOF | $233.82 | -4.49% | 108.3B | 40.74 | $5.74 | +1.92% |
| ESLOY | $116.69 | -3.55% | 108.1B | 40.53 | $2.88 | +1.92% |
| MECNY | $88.63 | +0.00% | 107.5B | N/A | N/A | N/A |
| SOAGY | $47.91 | -2.84% | 70B | 92.12 | $0.52 | +0.33% |
| HOCPF | $187.00 | +0.00% | 63.2B | 48.57 | $3.85 | +0.86% |
| HOCPY | $172.87 | +0.54% | 58.4B | 45.21 | $3.82 | +0.74% |
| RSMDF | $21.96 | +0.00% | 32B | 22.64 | $0.97 | +1.01% |
| TRUMF | $13.79 | +11.48% | 20.3B | 24.62 | $0.56 | +1.36% |
Stock Comparison
EKTAY vs SRTOY Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SRTOY has a market cap of 181B. Regarding current trading prices, EKTAY is priced at $5.85, while SRTOY trades at $18.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas SRTOY's P/E ratio is 60.00. In terms of profitability, EKTAY's ROE is -0.00%, compared to SRTOY's ROE of +0.06%. Regarding short-term risk, EKTAY is less volatile compared to SRTOY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check SRTOY's competition here
EKTAY vs ESLOF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, ESLOF has a market cap of 108.3B. Regarding current trading prices, EKTAY is priced at $5.85, while ESLOF trades at $233.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas ESLOF's P/E ratio is 40.74. In terms of profitability, EKTAY's ROE is -0.00%, compared to ESLOF's ROE of +0.06%. Regarding short-term risk, EKTAY is more volatile compared to ESLOF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check ESLOF's competition here
EKTAY vs ESLOY Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, ESLOY has a market cap of 108.1B. Regarding current trading prices, EKTAY is priced at $5.85, while ESLOY trades at $116.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas ESLOY's P/E ratio is 40.53. In terms of profitability, EKTAY's ROE is -0.00%, compared to ESLOY's ROE of +0.06%. Regarding short-term risk, EKTAY is more volatile compared to ESLOY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check ESLOY's competition here
EKTAY vs MECNY Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, MECNY has a market cap of 107.5B. Regarding current trading prices, EKTAY is priced at $5.85, while MECNY trades at $88.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas MECNY's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.00%, compared to MECNY's ROE of +0.02%. Regarding short-term risk, EKTAY is more volatile compared to MECNY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check MECNY's competition here
EKTAY vs SOAGY Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SOAGY has a market cap of 70B. Regarding current trading prices, EKTAY is priced at $5.85, while SOAGY trades at $47.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas SOAGY's P/E ratio is 92.12. In terms of profitability, EKTAY's ROE is -0.00%, compared to SOAGY's ROE of +0.06%. Regarding short-term risk, EKTAY is more volatile compared to SOAGY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SOAGY's competition here
EKTAY vs HOCPF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, HOCPF has a market cap of 63.2B. Regarding current trading prices, EKTAY is priced at $5.85, while HOCPF trades at $187.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas HOCPF's P/E ratio is 48.57. In terms of profitability, EKTAY's ROE is -0.00%, compared to HOCPF's ROE of +0.25%. Regarding short-term risk, EKTAY is more volatile compared to HOCPF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check HOCPF's competition here
EKTAY vs HOCPY Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, HOCPY has a market cap of 58.4B. Regarding current trading prices, EKTAY is priced at $5.85, while HOCPY trades at $172.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas HOCPY's P/E ratio is 45.21. In terms of profitability, EKTAY's ROE is -0.00%, compared to HOCPY's ROE of +0.25%. Regarding short-term risk, EKTAY is more volatile compared to HOCPY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check HOCPY's competition here
EKTAY vs RSMDF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, RSMDF has a market cap of 32B. Regarding current trading prices, EKTAY is priced at $5.85, while RSMDF trades at $21.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas RSMDF's P/E ratio is 22.64. In terms of profitability, EKTAY's ROE is -0.00%, compared to RSMDF's ROE of +0.25%. Regarding short-term risk, EKTAY is less volatile compared to RSMDF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check RSMDF's competition here
EKTAY vs TRUMF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, TRUMF has a market cap of 20.3B. Regarding current trading prices, EKTAY is priced at $5.85, while TRUMF trades at $13.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas TRUMF's P/E ratio is 24.62. In terms of profitability, EKTAY's ROE is -0.00%, compared to TRUMF's ROE of +0.09%. Regarding short-term risk, EKTAY is less volatile compared to TRUMF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check TRUMF's competition here
EKTAY vs TRUMY Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, TRUMY has a market cap of 19B. Regarding current trading prices, EKTAY is priced at $5.85, while TRUMY trades at $12.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas TRUMY's P/E ratio is 23.02. In terms of profitability, EKTAY's ROE is -0.00%, compared to TRUMY's ROE of +0.09%. Regarding short-term risk, EKTAY is less volatile compared to TRUMY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check TRUMY's competition here
EKTAY vs SUVPF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SUVPF has a market cap of 18.7B. Regarding current trading prices, EKTAY is priced at $5.85, while SUVPF trades at $271.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas SUVPF's P/E ratio is 104.26. In terms of profitability, EKTAY's ROE is -0.00%, compared to SUVPF's ROE of +0.06%. Regarding short-term risk, EKTAY is less volatile compared to SUVPF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check SUVPF's competition here
EKTAY vs SDMHF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SDMHF has a market cap of 18B. Regarding current trading prices, EKTAY is priced at $5.85, while SDMHF trades at $185.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas SDMHF's P/E ratio is 58.54. In terms of profitability, EKTAY's ROE is -0.00%, compared to SDMHF's ROE of +0.07%. Regarding short-term risk, EKTAY is more volatile compared to SDMHF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SDMHF's competition here
EKTAY vs SAUHY Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SAUHY has a market cap of 16.4B. Regarding current trading prices, EKTAY is priced at $5.85, while SAUHY trades at $10.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas SAUHY's P/E ratio is 35.45. In terms of profitability, EKTAY's ROE is -0.00%, compared to SAUHY's ROE of +0.17%. Regarding short-term risk, EKTAY is less volatile compared to SAUHY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check SAUHY's competition here
EKTAY vs SAUHF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SAUHF has a market cap of 16.3B. Regarding current trading prices, EKTAY is priced at $5.85, while SAUHF trades at $101.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas SAUHF's P/E ratio is 35.52. In terms of profitability, EKTAY's ROE is -0.00%, compared to SAUHF's ROE of +0.17%. Regarding short-term risk, EKTAY is more volatile compared to SAUHF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SAUHF's competition here
EKTAY vs SARTF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SARTF has a market cap of 15.6B. Regarding current trading prices, EKTAY is priced at $5.85, while SARTF trades at $226.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas SARTF's P/E ratio is 87.05. In terms of profitability, EKTAY's ROE is -0.00%, compared to SARTF's ROE of +0.06%. Regarding short-term risk, EKTAY is more volatile compared to SARTF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SARTF's competition here
EKTAY vs CLPBY Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, CLPBY has a market cap of 15.6B. Regarding current trading prices, EKTAY is priced at $5.85, while CLPBY trades at $6.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas CLPBY's P/E ratio is 25.59. In terms of profitability, EKTAY's ROE is -0.00%, compared to CLPBY's ROE of +0.25%. Regarding short-term risk, EKTAY is more volatile compared to CLPBY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check CLPBY's competition here
EKTAY vs CLPBF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, CLPBF has a market cap of 14.5B. Regarding current trading prices, EKTAY is priced at $5.85, while CLPBF trades at $69.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas CLPBF's P/E ratio is 25.07. In terms of profitability, EKTAY's ROE is -0.00%, compared to CLPBF's ROE of +0.25%. Regarding short-term risk, EKTAY is more volatile compared to CLPBF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check CLPBF's competition here
EKTAY vs SSSGY Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SSSGY has a market cap of 14.5B. Regarding current trading prices, EKTAY is priced at $5.85, while SSSGY trades at $41.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas SSSGY's P/E ratio is 80.59. In terms of profitability, EKTAY's ROE is -0.00%, compared to SSSGY's ROE of +0.06%. Regarding short-term risk, EKTAY is more volatile compared to SSSGY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SSSGY's competition here
EKTAY vs FSPKF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, FSPKF has a market cap of 13.1B. Regarding current trading prices, EKTAY is priced at $5.85, while FSPKF trades at $22.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas FSPKF's P/E ratio is 50.70. In terms of profitability, EKTAY's ROE is -0.00%, compared to FSPKF's ROE of +0.30%. Regarding short-term risk, EKTAY is more volatile compared to FSPKF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check FSPKF's competition here
EKTAY vs OCPNF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, OCPNF has a market cap of 9B. Regarding current trading prices, EKTAY is priced at $5.85, while OCPNF trades at $8.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas OCPNF's P/E ratio is 14.93. In terms of profitability, EKTAY's ROE is -0.00%, compared to OCPNF's ROE of +0.11%. Regarding short-term risk, EKTAY is less volatile compared to OCPNF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check OCPNF's competition here
EKTAY vs CNVVF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, CNVVF has a market cap of 6.6B. Regarding current trading prices, EKTAY is priced at $5.85, while CNVVF trades at $3.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas CNVVF's P/E ratio is 37.78. In terms of profitability, EKTAY's ROE is -0.00%, compared to CNVVF's ROE of +0.11%. Regarding short-term risk, EKTAY is less volatile compared to CNVVF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check CNVVF's competition here
EKTAY vs CNVVY Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, CNVVY has a market cap of 6.1B. Regarding current trading prices, EKTAY is priced at $5.85, while CNVVY trades at $12.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas CNVVY's P/E ratio is 36.86. In terms of profitability, EKTAY's ROE is -0.00%, compared to CNVVY's ROE of +0.10%. Regarding short-term risk, EKTAY is more volatile compared to CNVVY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check CNVVY's competition here
EKTAY vs SSMXF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SSMXF has a market cap of 5.6B. Regarding current trading prices, EKTAY is priced at $5.85, while SSMXF trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas SSMXF's P/E ratio is 19.15. In terms of profitability, EKTAY's ROE is -0.00%, compared to SSMXF's ROE of +0.09%. Regarding short-term risk, EKTAY is more volatile compared to SSMXF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SSMXF's competition here
EKTAY vs AHICF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, AHICF has a market cap of 5.4B. Regarding current trading prices, EKTAY is priced at $5.85, while AHICF trades at $20.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas AHICF's P/E ratio is 48.50. In terms of profitability, EKTAY's ROE is -0.00%, compared to AHICF's ROE of +0.12%. Regarding short-term risk, EKTAY is less volatile compared to AHICF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check AHICF's competition here
EKTAY vs SSMXY Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SSMXY has a market cap of 5.4B. Regarding current trading prices, EKTAY is priced at $5.85, while SSMXY trades at $8.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas SSMXY's P/E ratio is 19.27. In terms of profitability, EKTAY's ROE is -0.00%, compared to SSMXY's ROE of +0.09%. Regarding short-term risk, EKTAY is more volatile compared to SSMXY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SSMXY's competition here
EKTAY vs YPHDF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, YPHDF has a market cap of 5.2B. Regarding current trading prices, EKTAY is priced at $5.85, while YPHDF trades at $381.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas YPHDF's P/E ratio is 21.01. In terms of profitability, EKTAY's ROE is -0.00%, compared to YPHDF's ROE of +0.30%. Regarding short-term risk, EKTAY is more volatile compared to YPHDF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check YPHDF's competition here
EKTAY vs ADDLF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, ADDLF has a market cap of 4.9B. Regarding current trading prices, EKTAY is priced at $5.85, while ADDLF trades at $42.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas ADDLF's P/E ratio is 61.76. In terms of profitability, EKTAY's ROE is -0.00%, compared to ADDLF's ROE of +0.11%. Regarding short-term risk, EKTAY is less volatile compared to ADDLF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check ADDLF's competition here
EKTAY vs FLMNF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, FLMNF has a market cap of 4.4B. Regarding current trading prices, EKTAY is priced at $5.85, while FLMNF trades at $52.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas FLMNF's P/E ratio is 20.97. In terms of profitability, EKTAY's ROE is -0.00%, compared to FLMNF's ROE of +0.20%. Regarding short-term risk, EKTAY is more volatile compared to FLMNF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check FLMNF's competition here
EKTAY vs FLMNY Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, FLMNY has a market cap of 4.2B. Regarding current trading prices, EKTAY is priced at $5.85, while FLMNY trades at $9.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas FLMNY's P/E ratio is 19.87. In terms of profitability, EKTAY's ROE is -0.00%, compared to FLMNY's ROE of +0.20%. Regarding short-term risk, EKTAY is more volatile compared to FLMNY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check FLMNY's competition here
EKTAY vs ANSLF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, ANSLF has a market cap of 3.3B. Regarding current trading prices, EKTAY is priced at $5.85, while ANSLF trades at $22.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas ANSLF's P/E ratio is 32.49. In terms of profitability, EKTAY's ROE is -0.00%, compared to ANSLF's ROE of +0.07%. Regarding short-term risk, EKTAY is more volatile compared to ANSLF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check ANSLF's competition here
EKTAY vs SHWGF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SHWGF has a market cap of 3.3B. Regarding current trading prices, EKTAY is priced at $5.85, while SHWGF trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas SHWGF's P/E ratio is 12.17. In terms of profitability, EKTAY's ROE is -0.00%, compared to SHWGF's ROE of +0.08%. Regarding short-term risk, EKTAY is more volatile compared to SHWGF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SHWGF's competition here
EKTAY vs ANSLY Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, ANSLY has a market cap of 3B. Regarding current trading prices, EKTAY is priced at $5.85, while ANSLY trades at $84.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas ANSLY's P/E ratio is 22.63. In terms of profitability, EKTAY's ROE is -0.00%, compared to ANSLY's ROE of +0.07%. Regarding short-term risk, EKTAY is more volatile compared to ANSLY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check ANSLY's competition here
EKTAY vs SHWGY Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SHWGY has a market cap of 2.9B. Regarding current trading prices, EKTAY is priced at $5.85, while SHWGY trades at $2.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas SHWGY's P/E ratio is 10.20. In terms of profitability, EKTAY's ROE is -0.00%, compared to SHWGY's ROE of +0.08%. Regarding short-term risk, EKTAY is more volatile compared to SHWGY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SHWGY's competition here
EKTAY vs CZMWF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, CZMWF has a market cap of 2.6B. Regarding current trading prices, EKTAY is priced at $5.85, while CZMWF trades at $30.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas CZMWF's P/E ratio is 16.04. In terms of profitability, EKTAY's ROE is -0.00%, compared to CZMWF's ROE of +0.07%. Regarding short-term risk, EKTAY is less volatile compared to CZMWF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check CZMWF's competition here
EKTAY vs CZMWY Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, CZMWY has a market cap of 2.4B. Regarding current trading prices, EKTAY is priced at $5.85, while CZMWY trades at $26.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas CZMWY's P/E ratio is 14.62. In terms of profitability, EKTAY's ROE is -0.00%, compared to CZMWY's ROE of +0.06%. Regarding short-term risk, EKTAY is more volatile compared to CZMWY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check CZMWY's competition here
EKTAY vs TCGGY Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, TCGGY has a market cap of 2.3B. Regarding current trading prices, EKTAY is priced at $5.85, while TCGGY trades at $36.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas TCGGY's P/E ratio is 27.27. In terms of profitability, EKTAY's ROE is -0.00%, compared to TCGGY's ROE of +0.05%. Regarding short-term risk, EKTAY is less volatile compared to TCGGY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check TCGGY's competition here
EKTAY vs EKTAF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, EKTAF has a market cap of 2.3B. Regarding current trading prices, EKTAY is priced at $5.85, while EKTAF trades at $6.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas EKTAF's P/E ratio is -620.00. In terms of profitability, EKTAY's ROE is -0.00%, compared to EKTAF's ROE of -0.00%. Regarding short-term risk, EKTAY is more volatile compared to EKTAF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check EKTAF's competition here
EKTAY vs TCHBF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, TCHBF has a market cap of 2B. Regarding current trading prices, EKTAY is priced at $5.85, while TCHBF trades at $156.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas TCHBF's P/E ratio is 24.54. In terms of profitability, EKTAY's ROE is -0.00%, compared to TCHBF's ROE of +0.05%. Regarding short-term risk, EKTAY is more volatile compared to TCHBF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check TCHBF's competition here
EKTAY vs NPRRF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, NPRRF has a market cap of 1.6B. Regarding current trading prices, EKTAY is priced at $5.85, while NPRRF trades at $9.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas NPRRF's P/E ratio is 26.92. In terms of profitability, EKTAY's ROE is -0.00%, compared to NPRRF's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to NPRRF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check NPRRF's competition here
EKTAY vs BOEUF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, BOEUF has a market cap of 1.5B. Regarding current trading prices, EKTAY is priced at $5.85, while BOEUF trades at $22.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas BOEUF's P/E ratio is 98.10. In terms of profitability, EKTAY's ROE is -0.00%, compared to BOEUF's ROE of +0.18%. Regarding short-term risk, EKTAY is less volatile compared to BOEUF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check BOEUF's competition here
EKTAY vs TGLVY Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, TGLVY has a market cap of 1.3B. Regarding current trading prices, EKTAY is priced at $5.85, while TGLVY trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas TGLVY's P/E ratio is 31.51. In terms of profitability, EKTAY's ROE is -0.00%, compared to TGLVY's ROE of +0.03%. Regarding short-term risk, EKTAY is less volatile compared to TGLVY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check TGLVY's competition here
EKTAY vs SAFLY Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SAFLY has a market cap of 1.2B. Regarding current trading prices, EKTAY is priced at $5.85, while SAFLY trades at $4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas SAFLY's P/E ratio is 15.38. In terms of profitability, EKTAY's ROE is -0.00%, compared to SAFLY's ROE of +0.11%. Regarding short-term risk, EKTAY is more volatile compared to SAFLY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SAFLY's competition here
EKTAY vs BITGF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, BITGF has a market cap of 1.2B. Regarding current trading prices, EKTAY is priced at $5.85, while BITGF trades at $15.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas BITGF's P/E ratio is 45.50. In terms of profitability, EKTAY's ROE is -0.00%, compared to BITGF's ROE of +0.05%. Regarding short-term risk, EKTAY is more volatile compared to BITGF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check BITGF's competition here
EKTAY vs PBHDF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, PBHDF has a market cap of 1.2B. Regarding current trading prices, EKTAY is priced at $5.85, while PBHDF trades at $19.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas PBHDF's P/E ratio is 12.74. In terms of profitability, EKTAY's ROE is -0.00%, compared to PBHDF's ROE of +0.07%. Regarding short-term risk, EKTAY is more volatile compared to PBHDF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check PBHDF's competition here
EKTAY vs TDVXF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, TDVXF has a market cap of 912M. Regarding current trading prices, EKTAY is priced at $5.85, while TDVXF trades at $8.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas TDVXF's P/E ratio is 50.82. In terms of profitability, EKTAY's ROE is -0.00%, compared to TDVXF's ROE of +0.32%. Regarding short-term risk, EKTAY is less volatile compared to TDVXF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check TDVXF's competition here
EKTAY vs SAFLF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SAFLF has a market cap of 906.4M. Regarding current trading prices, EKTAY is priced at $5.85, while SAFLF trades at $2.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas SAFLF's P/E ratio is 17.77. In terms of profitability, EKTAY's ROE is -0.00%, compared to SAFLF's ROE of +0.11%. Regarding short-term risk, EKTAY is more volatile compared to SAFLF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SAFLF's competition here
EKTAY vs KSRBF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, KSRBF has a market cap of 841.7M. Regarding current trading prices, EKTAY is priced at $5.85, while KSRBF trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas KSRBF's P/E ratio is 33.29. In terms of profitability, EKTAY's ROE is -0.00%, compared to KSRBF's ROE of +0.04%. Regarding short-term risk, EKTAY is more volatile compared to KSRBF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check KSRBF's competition here
EKTAY vs HGYMF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, HGYMF has a market cap of 754.4M. Regarding current trading prices, EKTAY is priced at $5.85, while HGYMF trades at $34.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas HGYMF's P/E ratio is 184.16. In terms of profitability, EKTAY's ROE is -0.00%, compared to HGYMF's ROE of +0.00%. Regarding short-term risk, EKTAY is more volatile compared to HGYMF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check HGYMF's competition here
EKTAY vs GRRMF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, GRRMF has a market cap of 748.1M. Regarding current trading prices, EKTAY is priced at $5.85, while GRRMF trades at $21.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas GRRMF's P/E ratio is 27.42. In terms of profitability, EKTAY's ROE is -0.00%, compared to GRRMF's ROE of +0.02%. Regarding short-term risk, EKTAY is more volatile compared to GRRMF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check GRRMF's competition here
EKTAY vs NNCSF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, NNCSF has a market cap of 664.3M. Regarding current trading prices, EKTAY is priced at $5.85, while NNCSF trades at $2.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas NNCSF's P/E ratio is 43.80. In terms of profitability, EKTAY's ROE is -0.00%, compared to NNCSF's ROE of +0.10%. Regarding short-term risk, EKTAY is more volatile compared to NNCSF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check NNCSF's competition here
EKTAY vs JNDOF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, JNDOF has a market cap of 531M. Regarding current trading prices, EKTAY is priced at $5.85, while JNDOF trades at $22.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas JNDOF's P/E ratio is 47.40. In terms of profitability, EKTAY's ROE is -0.00%, compared to JNDOF's ROE of +0.29%. Regarding short-term risk, EKTAY is more volatile compared to JNDOF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check JNDOF's competition here
EKTAY vs SPMXF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SPMXF has a market cap of 458.6M. Regarding current trading prices, EKTAY is priced at $5.85, while SPMXF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas SPMXF's P/E ratio is -15.00. In terms of profitability, EKTAY's ROE is -0.00%, compared to SPMXF's ROE of -0.07%. Regarding short-term risk, EKTAY is less volatile compared to SPMXF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check SPMXF's competition here
EKTAY vs CLHLF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, CLHLF has a market cap of 365.5M. Regarding current trading prices, EKTAY is priced at $5.85, while CLHLF trades at $61.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas CLHLF's P/E ratio is 27.93. In terms of profitability, EKTAY's ROE is -0.00%, compared to CLHLF's ROE of +0.14%. Regarding short-term risk, EKTAY is more volatile compared to CLHLF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check CLHLF's competition here
EKTAY vs TSNLF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, TSNLF has a market cap of 287.6M. Regarding current trading prices, EKTAY is priced at $5.85, while TSNLF trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas TSNLF's P/E ratio is 27.27. In terms of profitability, EKTAY's ROE is -0.00%, compared to TSNLF's ROE of +0.24%. Regarding short-term risk, EKTAY is less volatile compared to TSNLF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check TSNLF's competition here
EKTAY vs GUERF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, GUERF has a market cap of 281M. Regarding current trading prices, EKTAY is priced at $5.85, while GUERF trades at $22.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas GUERF's P/E ratio is 8.19. In terms of profitability, EKTAY's ROE is -0.00%, compared to GUERF's ROE of +0.04%. Regarding short-term risk, EKTAY is more volatile compared to GUERF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check GUERF's competition here
EKTAY vs OPSSF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, OPSSF has a market cap of 247.4M. Regarding current trading prices, EKTAY is priced at $5.85, while OPSSF trades at $2.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas OPSSF's P/E ratio is -26.74. In terms of profitability, EKTAY's ROE is -0.00%, compared to OPSSF's ROE of -0.36%. Regarding short-term risk, EKTAY is more volatile compared to OPSSF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check OPSSF's competition here
EKTAY vs EEOIF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, EEOIF has a market cap of 63.4M. Regarding current trading prices, EKTAY is priced at $5.85, while EEOIF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas EEOIF's P/E ratio is -2.42. In terms of profitability, EKTAY's ROE is -0.00%, compared to EEOIF's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to EEOIF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check EEOIF's competition here
EKTAY vs OTCFF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, OTCFF has a market cap of 16.1M. Regarding current trading prices, EKTAY is priced at $5.85, while OTCFF trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas OTCFF's P/E ratio is -10.14. In terms of profitability, EKTAY's ROE is -0.00%, compared to OTCFF's ROE of +1.24%. Regarding short-term risk, EKTAY is more volatile compared to OTCFF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check OTCFF's competition here
EKTAY vs UEEC Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, UEEC has a market cap of 15M. Regarding current trading prices, EKTAY is priced at $5.85, while UEEC trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas UEEC's P/E ratio is -2.90. In terms of profitability, EKTAY's ROE is -0.00%, compared to UEEC's ROE of +1.00%. Regarding short-term risk, EKTAY is less volatile compared to UEEC. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check UEEC's competition here
EKTAY vs BLMHF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, BLMHF has a market cap of 5.2M. Regarding current trading prices, EKTAY is priced at $5.85, while BLMHF trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas BLMHF's P/E ratio is 1.56. In terms of profitability, EKTAY's ROE is -0.00%, compared to BLMHF's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to BLMHF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check BLMHF's competition here
EKTAY vs PXMVF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, PXMVF has a market cap of 4.6M. Regarding current trading prices, EKTAY is priced at $5.85, while PXMVF trades at $1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas PXMVF's P/E ratio is -0.17. In terms of profitability, EKTAY's ROE is -0.00%, compared to PXMVF's ROE of -6.46%. Regarding short-term risk, EKTAY is less volatile compared to PXMVF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check PXMVF's competition here
EKTAY vs CBSC Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, CBSC has a market cap of 4.5M. Regarding current trading prices, EKTAY is priced at $5.85, while CBSC trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas CBSC's P/E ratio is -4.00. In terms of profitability, EKTAY's ROE is -0.00%, compared to CBSC's ROE of +0.93%. Regarding short-term risk, EKTAY is more volatile compared to CBSC. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check CBSC's competition here
EKTAY vs MCDA Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, MCDA has a market cap of 4.2M. Regarding current trading prices, EKTAY is priced at $5.85, while MCDA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas MCDA's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.00%, compared to MCDA's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to MCDA. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check MCDA's competition here
EKTAY vs GVDI Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, GVDI has a market cap of 4.2M. Regarding current trading prices, EKTAY is priced at $5.85, while GVDI trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas GVDI's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.00%, compared to GVDI's ROE of +0.00%. Regarding short-term risk, EKTAY is more volatile compared to GVDI. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check GVDI's competition here
EKTAY vs RSCF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, RSCF has a market cap of 4M. Regarding current trading prices, EKTAY is priced at $5.85, while RSCF trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas RSCF's P/E ratio is -4.66. In terms of profitability, EKTAY's ROE is -0.00%, compared to RSCF's ROE of +0.03%. Regarding short-term risk, EKTAY is more volatile compared to RSCF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check RSCF's competition here
EKTAY vs NSTGQ Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, NSTGQ has a market cap of 3.3M. Regarding current trading prices, EKTAY is priced at $5.85, while NSTGQ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas NSTGQ's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.00%, compared to NSTGQ's ROE of N/A. Regarding short-term risk, EKTAY is less volatile compared to NSTGQ. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check NSTGQ's competition here
EKTAY vs TUTH Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, TUTH has a market cap of 3M. Regarding current trading prices, EKTAY is priced at $5.85, while TUTH trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas TUTH's P/E ratio is -1.18. In terms of profitability, EKTAY's ROE is -0.00%, compared to TUTH's ROE of +0.27%. Regarding short-term risk, EKTAY is more volatile compared to TUTH. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check TUTH's competition here
EKTAY vs ECIA Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, ECIA has a market cap of 1.9M. Regarding current trading prices, EKTAY is priced at $5.85, while ECIA trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas ECIA's P/E ratio is -5.00. In terms of profitability, EKTAY's ROE is -0.00%, compared to ECIA's ROE of -0.22%. Regarding short-term risk, EKTAY is more volatile compared to ECIA. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check ECIA's competition here
EKTAY vs YBGJ Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, YBGJ has a market cap of 1.8M. Regarding current trading prices, EKTAY is priced at $5.85, while YBGJ trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas YBGJ's P/E ratio is -0.75. In terms of profitability, EKTAY's ROE is -0.00%, compared to YBGJ's ROE of +0.39%. Regarding short-term risk, EKTAY is less volatile compared to YBGJ. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check YBGJ's competition here
EKTAY vs OJSY Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, OJSY has a market cap of 454.3K. Regarding current trading prices, EKTAY is priced at $5.85, while OJSY trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas OJSY's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.00%, compared to OJSY's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to OJSY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check OJSY's competition here
EKTAY vs PDMI Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, PDMI has a market cap of 324.9K. Regarding current trading prices, EKTAY is priced at $5.85, while PDMI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas PDMI's P/E ratio is -0.01. In terms of profitability, EKTAY's ROE is -0.00%, compared to PDMI's ROE of +0.19%. Regarding short-term risk, EKTAY is more volatile compared to PDMI. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check PDMI's competition here
EKTAY vs WHSI Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, WHSI has a market cap of 182.7K. Regarding current trading prices, EKTAY is priced at $5.85, while WHSI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas WHSI's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.00%, compared to WHSI's ROE of +0.84%. Regarding short-term risk, EKTAY is more volatile compared to WHSI. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check WHSI's competition here
EKTAY vs BLFE Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, BLFE has a market cap of 156.7K. Regarding current trading prices, EKTAY is priced at $5.85, while BLFE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas BLFE's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.00%, compared to BLFE's ROE of +3.67%. Regarding short-term risk, EKTAY is more volatile compared to BLFE. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check BLFE's competition here
EKTAY vs QTXB Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, QTXB has a market cap of 118K. Regarding current trading prices, EKTAY is priced at $5.85, while QTXB trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas QTXB's P/E ratio is -0.05. In terms of profitability, EKTAY's ROE is -0.00%, compared to QTXB's ROE of +0.19%. Regarding short-term risk, EKTAY is less volatile compared to QTXB. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check QTXB's competition here
EKTAY vs IMTH Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, IMTH has a market cap of 89.8K. Regarding current trading prices, EKTAY is priced at $5.85, while IMTH trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas IMTH's P/E ratio is -0.03. In terms of profitability, EKTAY's ROE is -0.00%, compared to IMTH's ROE of -0.32%. Regarding short-term risk, EKTAY is less volatile compared to IMTH. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check IMTH's competition here
EKTAY vs LANZ Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, LANZ has a market cap of 74.5K. Regarding current trading prices, EKTAY is priced at $5.85, while LANZ trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas LANZ's P/E ratio is 2.70. In terms of profitability, EKTAY's ROE is -0.00%, compared to LANZ's ROE of +0.01%. Regarding short-term risk, EKTAY is less volatile compared to LANZ. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check LANZ's competition here
EKTAY vs CEOS Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, CEOS has a market cap of 35.9K. Regarding current trading prices, EKTAY is priced at $5.85, while CEOS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas CEOS's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.00%, compared to CEOS's ROE of +0.40%. Regarding short-term risk, EKTAY is less volatile compared to CEOS. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check CEOS's competition here
EKTAY vs GMVDF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, GMVDF has a market cap of 26K. Regarding current trading prices, EKTAY is priced at $5.85, while GMVDF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas GMVDF's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.00%, compared to GMVDF's ROE of +3.68%. Regarding short-term risk, EKTAY is more volatile compared to GMVDF. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check GMVDF's competition here
EKTAY vs REMI Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, REMI has a market cap of 14K. Regarding current trading prices, EKTAY is priced at $5.85, while REMI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas REMI's P/E ratio is -0.07. In terms of profitability, EKTAY's ROE is -0.00%, compared to REMI's ROE of -0.11%. Regarding short-term risk, EKTAY is less volatile compared to REMI. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check REMI's competition here
EKTAY vs SDCCQ Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SDCCQ has a market cap of 13.4K. Regarding current trading prices, EKTAY is priced at $5.85, while SDCCQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas SDCCQ's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.00%, compared to SDCCQ's ROE of -0.61%. Regarding short-term risk, EKTAY is more volatile compared to SDCCQ. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SDCCQ's competition here
EKTAY vs MDIT Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, MDIT has a market cap of 8.7K. Regarding current trading prices, EKTAY is priced at $5.85, while MDIT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas MDIT's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.00%, compared to MDIT's ROE of -0.99%. Regarding short-term risk, EKTAY is more volatile compared to MDIT. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check MDIT's competition here
EKTAY vs ASFX Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, ASFX has a market cap of 7K. Regarding current trading prices, EKTAY is priced at $5.85, while ASFX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas ASFX's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.00%, compared to ASFX's ROE of +0.00%. Regarding short-term risk, EKTAY is less volatile compared to ASFX. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check ASFX's competition here
EKTAY vs DGEN Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, DGEN has a market cap of 3.9K. Regarding current trading prices, EKTAY is priced at $5.85, while DGEN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas DGEN's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.00%, compared to DGEN's ROE of +0.05%. Regarding short-term risk, EKTAY is more volatile compared to DGEN. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check DGEN's competition here
EKTAY vs SVSO Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SVSO has a market cap of 2.6K. Regarding current trading prices, EKTAY is priced at $5.85, while SVSO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas SVSO's P/E ratio is -0.01. In terms of profitability, EKTAY's ROE is -0.00%, compared to SVSO's ROE of +0.17%. Regarding short-term risk, EKTAY is more volatile compared to SVSO. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SVSO's competition here
EKTAY vs LFPI Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, LFPI has a market cap of 2.1K. Regarding current trading prices, EKTAY is priced at $5.85, while LFPI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas LFPI's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.00%, compared to LFPI's ROE of -4.85%. Regarding short-term risk, EKTAY is less volatile compared to LFPI. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check LFPI's competition here
EKTAY vs INND Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, INND has a market cap of 1.8K. Regarding current trading prices, EKTAY is priced at $5.85, while INND trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas INND's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.00%, compared to INND's ROE of +0.12%. Regarding short-term risk, EKTAY is less volatile compared to INND. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check INND's competition here
EKTAY vs SEYE Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SEYE has a market cap of 1.2K. Regarding current trading prices, EKTAY is priced at $5.85, while SEYE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas SEYE's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.00%, compared to SEYE's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to SEYE. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SEYE's competition here
EKTAY vs BGMD Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, BGMD has a market cap of 1.1K. Regarding current trading prices, EKTAY is priced at $5.85, while BGMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas BGMD's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.00%, compared to BGMD's ROE of +7.47%. Regarding short-term risk, EKTAY is more volatile compared to BGMD. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check BGMD's competition here
EKTAY vs ADLI Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, ADLI has a market cap of 1K. Regarding current trading prices, EKTAY is priced at $5.85, while ADLI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas ADLI's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.00%, compared to ADLI's ROE of +1.36%. Regarding short-term risk, EKTAY is less volatile compared to ADLI. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check ADLI's competition here
EKTAY vs VSMD Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, VSMD has a market cap of 802. Regarding current trading prices, EKTAY is priced at $5.85, while VSMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas VSMD's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.00%, compared to VSMD's ROE of +3.15%. Regarding short-term risk, EKTAY is less volatile compared to VSMD. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check VSMD's competition here
EKTAY vs TEVNF Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, TEVNF has a market cap of 744. Regarding current trading prices, EKTAY is priced at $5.85, while TEVNF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas TEVNF's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.00%, compared to TEVNF's ROE of +3.22%. Regarding short-term risk, EKTAY is less volatile compared to TEVNF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAY.Check TEVNF's competition here
EKTAY vs HRAL Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, HRAL has a market cap of 396. Regarding current trading prices, EKTAY is priced at $5.85, while HRAL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas HRAL's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.00%, compared to HRAL's ROE of +0.18%. Regarding short-term risk, EKTAY is more volatile compared to HRAL. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check HRAL's competition here
EKTAY vs MICRD Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, MICRD has a market cap of 317. Regarding current trading prices, EKTAY is priced at $5.85, while MICRD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas MICRD's P/E ratio is -0.00. In terms of profitability, EKTAY's ROE is -0.00%, compared to MICRD's ROE of -0.25%. Regarding short-term risk, EKTAY is more volatile compared to MICRD. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check MICRD's competition here
EKTAY vs RGBOQ Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, RGBOQ has a market cap of 97. Regarding current trading prices, EKTAY is priced at $5.85, while RGBOQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas RGBOQ's P/E ratio is -0.00. In terms of profitability, EKTAY's ROE is -0.00%, compared to RGBOQ's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to RGBOQ. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check RGBOQ's competition here
EKTAY vs SECI Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, SECI has a market cap of 31. Regarding current trading prices, EKTAY is priced at $5.85, while SECI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas SECI's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.00%, compared to SECI's ROE of -0.00%. Regarding short-term risk, EKTAY is more volatile compared to SECI. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check SECI's competition here
EKTAY vs VTEQ Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, VTEQ has a market cap of 1. Regarding current trading prices, EKTAY is priced at $5.85, while VTEQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas VTEQ's P/E ratio is -0.00. In terms of profitability, EKTAY's ROE is -0.00%, compared to VTEQ's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to VTEQ. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check VTEQ's competition here
EKTAY vs OCPNY Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, OCPNY has a market cap of 0. Regarding current trading prices, EKTAY is priced at $5.85, while OCPNY trades at $18.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas OCPNY's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.00%, compared to OCPNY's ROE of +0.26%. Regarding short-term risk, EKTAY is more volatile compared to OCPNY. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check OCPNY's competition here
EKTAY vs MEDVD Comparison March 2026
EKTAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAY stands at 2.2B. In comparison, MEDVD has a market cap of 0. Regarding current trading prices, EKTAY is priced at $5.85, while MEDVD trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAY currently has a P/E ratio of -588.00, whereas MEDVD's P/E ratio is N/A. In terms of profitability, EKTAY's ROE is -0.00%, compared to MEDVD's ROE of N/A. Regarding short-term risk, EKTAY is more volatile compared to MEDVD. This indicates potentially higher risk in terms of short-term price fluctuations for EKTAY.Check MEDVD's competition here